Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

APRI $1.85 0.1700 +10.12%
BPTH $1.20 0.0900 +8.11%
ONCY $0.54 0.0399 +7.98%
PVCT $0.56 0.0300 +5.66%
MEIP $1.77 0.0700 +4.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

LOXO $17.12 -1.0400 -5.73%
GERN $4.15 -0.2500 -5.68%
BLRX $2.50 -0.1500 -5.66%
MNTA $21.27 -1.1600 -5.17%
ENZN $1.21 -0.0600 -4.72%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Nonsolid Lung Nodules Followed Safely With CT

(MedPage Today/The Gupta Guide) June 23, 2015 - Surveillance of nonsolid lung nodules with CT imaging detected all nodules in transition to part-solid status, enabling curative treatment and avoiding treatment in most cases, a large retrospective study showed.
read article (free registration required) 



Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia

(Morningstar) June 24, 2015 - Celator Pharmaceuticals, Inc. today announced final induction response rate results (complete remission plus complete remission with incomplete hematologic recovery, or CR+CRi) in the Phase 3 study comparing CPX-351 (cytarabine:daunorubicin) liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia (AML).
read article 



Report: Viagra Doesn't Cause Melanoma But The Viagra Lifestyle Might

(Forbes) June 23, 2015 - A major research endeavor seeks answers on whether there’s a link between ED drugs and skin cancer.
read article 



A Bill Would Prevent Drug Makers From Frustrating Generic Rivals

(Wall Street Journal/Pharmalot blog) June 23, 2015 - For the second time in less than a year, a pair of lawmakers has introduced a bill designed to end a practice that generic drug makers complain is used by brand-name counterparts to thwart competition.
read article (paid subscription required) 



Cancer Doctors Offer Way to Compare Medicines, Including by Cost

(New York Times) June 22, 2015 - Alarmed by the rapid escalation in the price of cancer drugs, the nation’s leading oncology society unveiled on Monday a new way for doctors and patients to evaluate different treatments — one that pointedly includes a medicine’s cost as well as its effectiveness and side effects.
read article 



Maryland Gov. Larry Hogan Says He Has ‘Advanced’ Form Of Cancer

(Washington Post) June 22, 2015 - An emotional Maryland Gov. Larry Hogan disclosed Monday that he has been diagnosed with late stage 3 non-Hodgkin’s lymphoma, which he called “a very advanced and very aggressive” form of cancer.
read article (free registration required) 



FDA Approves New Antiplatelet Drug Used During Heart Procedure

(FDA.gov) June 22, 2015 - The U.S. Food and Drug Administration today approved Kengreal (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries, the blood vessels that supply blood to the heart.
read press release 



New England Cancer Specialists Receives National Recognition as an Oncology Medical Home

(KEYC News 12, CBS [N. Mankato, MN]) June 22, 2015 - On May 27th New England Cancer Specialists, one of the last remaining community-based, independent cancer practices in the region, received full accreditation from the Commission on Cancer (CoC) as an Oncology Medical Home.
read article 



Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

(Soligenix) June 23, 2015 - Soligenix, Inc. announced today that it will be working with the National Organization for Rare Disorders (NORD) and the Cutaneous Lymphoma Foundation (CLF) to educate and recruit patients for its pivotal Phase 3 clinical study of SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
read corporate press release 



BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca’s Aurora B Kinase Inhibitor Accurin AZD2811

(StreetInsider) June 23, 2015 - Collaboration with AstraZeneca results in second Accurin candidate to enter clinical development; promising AZD2811 data demonstrating tumor growth inhibition and prolonged drug exposure recently presented at the 2015 American Association of Cancer Research (AACR) Annual Meeting.
read article 



Calithera Biosciences Selects Immuno-Oncology Clinical Candidate CB-1158, an Oral Arginase Inhibitor for the Treatment of Cancer

(MarketWatch) June 23, 2015 - Calithera Biosciences, Inc. announced today at the JMP Securities Life Sciences Conference in New York City, the selection of CB-1158 as the clinical candidate for their immuno-oncology program targeting inhibition of arginase, a critical immunosuppressive enzyme secreted by myeloid-derived suppressor cells (MDSCs) in tumors.
read article 



How “Open-Label” Placebos Turn Fake Pills Into Real Treatment

(UAB The Mix) June 19, 2015 - A group of researchers at UAB and Harvard University are taking “open-label” placebo trials into a new patient population: cancer survivors. For men and women struggling with the crushing fatigue that often emerges in the years after treatment, the power of placebos may be just what they need.
read article 



In Twist, Scientists Join Tobacco Companies To Fight Cancer

(Reuters) June 23, 2015 - Scientists who have devoted years developing medicines to cure disease are now working for tobacco companies to make e-cigarettes.
read article 



Who Agency Says Insecticides Lindane And DDT Linked To Cancer

(Reuters) June 23, 2015 - The insecticide lindane, once widely used in agriculture and to treat human lice and scabies, causes cancer and has been specifically linked to non-Hodgkin lymphoma, the World Health Organization said on Tuesday.
read article 



Welcome To The Sharing Economy. Cancer Researchers Are Next.

(Xconomy) June 23, 2015 - A big plan for extramural sharing is underway, according to cancer researcher Charles Sawyer.
read article 



Caladrius Biosciences Announces First Patient Dosed in Phase 3 Immunotherapy Trial for Melanoma

(MarketWatch) June 23, 2015 - Caladrius Biosciences, Inc., a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today the dosing of the first patient in the Intus Phase 3 clinical trial.
read article 



TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

(CNNMoney) June 23, 2015 - TapImmune Inc. is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial.
read article 



Researchers Develop New Breath Test To Diagnose Oesophageal And Gastric Cancer

(Imperial College London [UK]) June 23, 2015 - Researchers have devised a breath test that can help doctors diagnose the early signs of oesophageal and gastric cancer in minutes.
read press release 



Many With Early Breast Cancer Have Too Many Imaging Tests

(Reuters Health) June 22, 2015 - Nearly nine in 10 women with early breast cancer have imaging exams to see if the cancer has spread, despite official recommendations against such tests, a new study suggests.
read article 



‘Smarter’ Ordering of Breast Biomarker Tests Could Save Millions in Health Care Dollars, Study Reveals

(Johns Hopkins Medicine) June 23, 2015 - A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health care spending without compromising care.
read press release 



New Multiple Myeloma Regimen Is Also Effective in Elderly

(Medscape Medical News) June 22, 2015 - A treatment regimen of lenalidomide and low-dose dexamethasone shows significant improvements in progression-free survival in patients over 75 similar to those under 75.
read article (free registration required) 



The Challenges of Incorporating Gene Panels Into Clinical Practice

(Medscape Oncology) June 22, 2015 - In the past several years, an increasing number of gene panel tests have become available for use in the clinic. At the recent annual meeting of the American Society of Clinical Oncology (ASCO), speakers discussed some of the controversies and clinical dilemmas surrounding these tests.
read article (free registration required) 



NICE’s New Symptom–Based Approach Will Help To Save Thousands Of Lives From Cancer

(NICE) June 23, 2015 - NICE has updated and redesigned its guideline to support GPs to recognise the signs and symptoms of 37 different cancers and refer people for the right tests faster.
read article 



Cancer Drugs Get A New Consumer's Guide

(Los Angeles Times/Science Now) June 22, 2015 - In a bid to inject clarity into the fast-moving, high-stakes world of cancer drugs, a task force of cancer doctors announced Monday that it has devised a decision-making aid to help physicians and their patients weigh the pluses and minuses of newly available options for treating malignancy, including their costs.
read article (free registration required) 



Current Blood Cancer Drug Prices Not Justified, MD Anderson Study Finds

(MD Anderson) June 22, 2015 - In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States.
read press release